Urcosimod phase 2 trial treating Neuropathic Corneal Pain (“NCP”) patients was initiated in October 2024 and designed as a double-masked, randomized, 12-week placebo-controlled trial.OKYO Pharma plans ...

The Digital Poverty Alliance (DPA) has launched an inquiry into digital inclusion in the healthcare sector amid government announcements to allocate billions to digital transformation. At a time where ...

NCIMB Limited ("NCIMB"), a leading microbiology services provider and owner of the UK’s largest industrial, food and marine bacterial culture collection, has secured a £1.7m investment from the ...

RetinAI US Inc. (RetinAI) and      Fundación Ver Salud (FVS) are pleased to jointly announce that LuxIA®, their co-developed innovative AI algorithm for Diabetic Retinopathy (DR) screening, has ...

Following MHRA approval, Stablepharma Ltd has commenced a Phase 1 clinical trial with its lead candidate, fridge-free tetanus and diphtheria vaccine, SPVX02. The Phase 1, first-in-human clinical trial ...

A recent video produced by Vapourtec highlights the patented automatic Variable Bed Flow Reactor (VBFR) demonstrating fully automated solid phase peptide synthesis (SPPS).The process begins with ...

Veranova, a global leader in the development and manufacturing of specialty and complex active pharmaceutical ingredients (APIs) for the pharmaceutical and biotech sectors, is proud to announce the ...

AstraZeneca is discontinuing the CAPItello-280 Phase III trial evaluating the efficacy and safety of Truqap (capivasertib) in combination with docetaxel and androgen-deprivation therapy (ADT) compared ...

On the last day of February every year is Rare Disease Day, a dedicated day to celebrate the rare disease community, including patients, families, caregivers, clinicians, researchers, regulators, and ...

Results from Operations for first quarter 2025 versus first quarter last year:Revenue: $3.35 billion versus $3.18 billionDiluted EPS: $2.52 versus $2.69Adjusted EPS: $3.84 versus $3.68Reaffirmed ...

As we have highlighted in prior blog posts, the ability to augment design characteristics with custom R code is especially relevant to the ever-evolving therapeutic area of oncology. As regulatory ...

Novavax, Inc. (Nasdaq: NVAX) today announced the appointment of Charles Newton to its board as an independent director. Mr. Newton brings extensive experience in public markets and healthcare ...